Article Text

Download PDFPDF

329 Hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer
  1. M Salvai1,
  2. RM Riege1,
  3. J Costa1,
  4. G Santillan2 and
  5. M Rosso1
  1. 1Grupo Gamma, Gynecology, Rosario, Argentina
  2. 2Instituto de Ginecología, Gynecology, Rosario, Argentina


Objectives To evaluate the disease-free survival rate in patients with ovarian cancer treated with hyperthermic intraperitoneal chemotherapy (HIPEC) and to analyze the complications related to the procedure.

Methods Retrospective, longitudinal observational study of patients diagnosed with ovarian cancer, who underwent cytoreduction surgery and intraoperative hyperthermic chemotherapy between January 1989 and January 2019, at the ‘‘‘‘‘Instituto de Ginecología’’’’’ and ‘‘‘‘‘Grupo Gamma’’’’’ of Rosario, Santa Fe, Argentina.

Results Of the total number of patients included (n: 43), 67.4% were alive without evidence of disease and 32.6% died because of their disease. The five-year disease-free survival was 68.5%. The prevalence of complications was 13.95% and they included grade 3–4 complications according to the toxicity scale. No deaths related to the technique were reported.

Conclusions Hyperthermic intraperitoneal chemotherapy is an efficient procedure. There was an apparent improvement in progression-free survival and overall survival with a low prevalence of complications.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.